Emergent BioSolutions — Third Quarter 2026 Earnings Summary

Emergent BioSolutions reported third-quarter 2026 total revenues of $110.0 million, a 52% decrease from the prior year period, driven primarily by timing-related fluctuations in U.S. government sales of medical countermeasures and lower over-the-counter NARCAN volumes. The company recorded a net loss of $32.7 million for the quarter, resulting in a net loss margin of 30%, while adjusted net loss was $18.7 million. Year-to-date 2026 revenues totaled $500.4 million, and the company revised its full-year 2026 revenue forecast downward to a range of $600 million to $645 million. Recent business updates include the retirement of CFO Rich Lindahl, the completion of a $75 million senior unsecured notes repurchase, and the award of a $24 million contract modification for CYFENDUS.